Fair Value Distribution — percentile bands
90.7% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-4.2%/yr
±2.9% · revenue growth to justify current price
FCF-Based Reverse DCF
-11.0%/yr
±2.8% · FCF growth to justify current price
THE GAP
Market pricing margin expansion or capex normalization
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockAltria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
MO delivered 4.4% adjusted EPS growth (.19→.42) but fell short of its mid-single digit CAGR goal (3.6% 3yr CAGR). NJOY ACE banned from US market via ITC patent ruling, triggering ~.9B impairment. Ciga...